Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.62 USD | +4.10% | +7.02% | +30.70% |
Apr. 19 | TScan Therapeutics Closes $150.1 Million Securities Offering | MT |
Apr. 17 | TScan Therapeutics Prices $150.1 Million Public Offering of Shares, Warrants | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+30.70% | 369M | - | ||
+2.07% | 42.75B | B | ||
+47.70% | 41.61B | A | ||
+12.18% | 41.34B | B- | ||
-12.36% | 26.59B | C | ||
+8.49% | 25.49B | B- | ||
-23.55% | 18.12B | B | ||
+30.76% | 12.24B | C+ | ||
-2.03% | 11.76B | C+ | ||
+8.54% | 11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- TCRX Stock
- Ratings TScan Therapeutics, Inc.